Intravenous Iron Therapy in Heart Failure Patients With Iron Deficiency: Benefits, Safety, and Guidelines

Area of Science:

• Cardiology
• Hematology
• Pharmacology

Background:

• Iron deficiency affects up to 50% of heart failure (HF) patients, impacting their health.
• Intravenous (IV) iron therapy is a potential treatment for iron deficiency in HF.
• Concerns exist regarding long-term cardiotoxicity and iron overload with IV iron.

Purpose of the Study:

• To review current literature on IV iron therapy for HF patients with iron deficiency.
• To evaluate the benefits of IV iron on quality of life, exercise capacity, and hospitalizations.
• To address safety concerns and provide an overview of current guidelines.

Main Methods:

• Literature review of studies on IV iron therapy in HF patients.
• Analysis of benefits, risks, and safety profiles of IV iron formulations.
• Examination of 2022 American College of Cardiology/American Heart Association guidelines.

Main Results:

• IV iron therapy shows promise in improving quality of life and exercise capacity.
• IV iron may reduce heart failure hospitalizations.
• Potential long-term cardiotoxic effects and iron overload risks need consideration.

Conclusions:

• IV iron therapy is a recommended treatment for eligible HF patients with iron deficiency.
• A balanced approach to iron replacement is crucial.
• Further research is needed for specific HF populations and IV iron formulations.